http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21652600

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't
endingPage 859
issn 1528-0020
0006-4971
issueIdentifier 11
pageRange 851-859
publicationName Blood
startingPage 851
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577
bibliographicCitation Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 Sep 12;134(11):851–9. PMID: 31340982; PMCID: PMC6742923.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_792d1a08d029c6d5cfc613412762f786
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7341-5720
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9768-7413
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_58c50547b81c9af2a82d799fa0e9e80c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9f8bce30ced4bac8488495bd8780afac
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8eaaa7604c8883cda81dfeb8a1ed8dfd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8009-4593
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efa30ec5f7e6c7a0d8ae0ca2b9ef0a30
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2188-6835
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_755aa110f5aad6750ed5378ebd69f308
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6177-7572
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83d70bdc498d8372c9a7e1bae2dab253
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a61b65d3900fd0b2115d59b8488eb7a1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_726a8cc16dd3ec05631df7664e837e7f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79a739e6d7eb30343ef8944feab00498
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbcf796c2741280607a2532806ed12c5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e8a4c83fb353143b6c126b0c41ae149
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_10836d1edf95c658cd3493d6b306c20a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9759-5017
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_070fdd6580117d750fdcf863a1fc7234
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e86f9cbfcf535d944dd000131b336dbe
date 2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/31340982
https://doi.org/10.1182/blood.2019001160
https://pubmed.ncbi.nlm.nih.gov/PMC6742923
isPartOf https://portal.issn.org/resource/ISSN/0006-4971
https://portal.issn.org/resource/ISSN/1528-0020
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1243
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
discusses http://id.nlm.nih.gov/mesh/M0018260
http://id.nlm.nih.gov/mesh/M000646711
http://id.nlm.nih.gov/mesh/M0018226
http://id.nlm.nih.gov/mesh/M0457532
http://id.nlm.nih.gov/mesh/M0474970
http://id.nlm.nih.gov/mesh/M0219038
http://id.nlm.nih.gov/mesh/M0016885
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_564f64348efdade903a3b83a985759d0
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135565884
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9720
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8306
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2064
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID404772479
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2066
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3717
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID695
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID640
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7006
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3702
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID660
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1956

Total number of triples: 67.